Portfoliotracker

Polaryx Therapeutics, Inc.

PLYX · NASDAQCM · Healthcare Biotechnology 27/100 E

1,670 $
▲ +0,000 (+0,00 %)
Trading delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 15:50
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score27 / 100 Market cap80,6 mil. $ P/E– Forward P/E– P/S– P/B7,4 EV/EBITDA– Dividend yield– FCF yield-7,20 % EPS-0,18 $ Net margin0,0 % Return on equity-135,5 % Beta– Debt / equity–
52-week range 1,67 to 48,91
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Employees
2
Country
United States
Fiscal year end
31. 12.
Data since
2. 2. 2026

Explore further

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account